Xiamen C&D Emerging Industry Equity Investment

Xiamen C&D Emerging Industry Equity Investment

Launched in 2014 as the dedicated equity investment arm of Xiamen C&D Group, the firm started with a broad mandate to back China’s strategic emerging industries. Its ultimate shareholder is the Xiamen SASAC, which positions the firm squarely inside the country’s state-capital machinery while allowing it to operate as a professionalized asset manager. General Manager and Chairman Cai Xiaofan heads a team that went from a first local deal in 2015 to managing a diversified portfolio across fund commitments, direct co-investments, and increasingly, secondary market transactions by 2025. Strategy execution covers early-stage venture, growth equity, pre-IPO rounds, and fund-of-funds commitments. The firm’s capital flows into three core verticals: healthcare (biopharma, medical devices, services), advanced manufacturing (new energy, semiconductors, smart manufacturing), and TMT/consumer (AI, smart hardware, food supply chains). Co-investors and portfolio exposures include Mango Wenchuang Fund in media and confirmed participation across over 100 fund partnerships and 200 direct deals. It also runs a noted secondary fund — Xinying No. 1 — which closed at RMB 500 million in late 2025 to buy LP positions, a signal of its deepening operational complexity. Operating from Xiamen headquarters and a substantial Shanghai office, the firm sources nationally. With over 80 professionals and a decade of investing behind it, scale has grown sharply: the firm surpassed RMB 300 billion in total managed assets in 2025 and carries an AA+ domestic credit rating. Recent operational moves include a RMB 400 million technology innovation bond issued in August 2025 at a 2.32% coupon and a landmark RMB 10 billion second-phase science and innovation mother fund launched with China’s National Social Security Fund. Cai’s team now frames its identity as a “venture capital industry chain operator” — a unique self-conception that signals its ambition to intermediate between LP capital, GP relationships, and direct deal flow. No other Chinese asset manager hybridizes a state-owned supply-chain conglomerate’s permanent capital with a full-stack primary market platform quite this way. The parent company runs commercial logistics across 170 countries and holds over RMB 600 billion in total assets, giving the investment team visibility into downstream demand, industrial capacity, and trade flows that pure financial LPs cannot replicate. This architecture — an AA+ rated LP with its own direct-investment muscle and an in-house secondary fund — creates a structural moat that blurs the line between allocator and operator.